Recent reports suggest that IGF (insulin-like growth factor)-I and IGFBP-3 (IGF-binding protein-3) have independent and opposing mechanistic effects on insulin. The aim of the present study was to assess the relationship between the IGF-I/IGFBP-3 ratio and the metabolic syndrome. We examined 3281 subjects (1463 men and 1818 women, aged 20-49 years), otherwise healthy adults, who participated in NHANES III (Third National Health and Nutrition Examination Survey), which has released measurements of IGF-I and IGFBP-3. Insulin resistance was estimated using the computer HOMA2 (homoeostatic model assessment 2) model. The updated ATP-III (Adult Treatment Panel III) definition of the metabolic syndrome was used. We applied adjusted logistic and linear regression models. After adjusting for age and race, men and women in the lowest quartile of the IGF-I/IGFBP-3 ratio were 3-fold more likely to meet the ATP-III definition of the metabolic syndrome and twice as likely to be insulin-resistant. Mean values of the IGF-I/IGFBP-3 ratio decreased significantly as the number of metabolic syndrome components increased (P < 0.0001, as determined by ANOVA). The area under the ROC (receiver operating characteristic) curve for detecting insulin resistance using the IGF-I/IGFBP-3 ratio was 0.760, significantly improving upon either protein alone (P = 0.01). In conclusion, the IGF-I/IGFBP-3 ratio is significantly associated with the metabolic syndrome. Calculating the ratio of these two proteins may provide insight into the metabolic syndrome clustering phenomenon.
INTRODUCTION
Epidemiological studies have suggested that higher IGF (insulin-like growth factor)-I concentrations are independently associated with a reduced risk of cardiovascular disease [1] [2] [3] . Low IGF-I concentrations have been reported to contribute to processes leading to plaque weakening, plaque rupture and acute coronary events [4, 5] . Furthermore, recent evidence suggests that low levels of IGF-I are related to the development of Type 2 diabetes [6, 7] . IGF-I may play an important role in glucose homoeostasis by enhancing glucose uptake and improving insulin sensitivity.
The biological effects of IGF-I are modulated by IGFBPs (IGF-binding proteins), such as IGFBP-3, which is the major binding protein (> 80 %) for IGF-I and circulates throughout the body controlling the access of IGF-I to cell-surface receptors, thus potentially playing an important role in glucose metabolism [8] [9] [10] [11] [12] [13] [14] [15] [16] . Furthermore, a previous animal study [17] has shown that IGF-I and IGFBP-3 have marked opposing and independent physiological effects on peripheral insulin action via central mechanisms, demonstrating the first acute in vivo effect of IGFBP-3 on insulin. Measurement of IGFBP-3 could be used as a surrogate for free IGF-I [3, 16] .
Although low IGF-I serum levels detect subjects at increased cardiovascular risk, high IGFBP-3 levels detect subjects that are prone to be insulin-resistant [12, 15, 16] . Therefore the IGF-I/IGFBP-3 ratio may represent a balance between cardiac and metabolic risk, raising the possibility of identifying subjects at a particular high cardiometabolic risk that could shed some insight into the risk-factor-clustering pathophysiology.
Given the release in October 2006 of data on IGF-I and IGFBP-3 from NHANES III (Third National Health and Nutrition Examination Survey), we identified a unique opportunity to study the relationship between the IGF-I/IGFBP-3 ratio and increased cardiometabolic risk. The aim of the present study was to assess whether the IGF-I/IGFBP-3 ratio was related to the metabolic syndrome. In particular, we posed the question of whether the IGF-I/IGFBP-3 ratio would improve upon the ability to predict high cardiometabolic risk than with either IGF-I or IGFBP-3 considered alone. To accomplish these aims, we used an otherwise healthy representative sample of the U.S. population of 20-49 years of age.
MATERIALS AND METHODS

Study Sample
NHANES III is a representative sample of the U.S. non-institutionalized civilian population. It consists of a periodic survey conducted by the United States National Center for Health Statistics designed to provide an estimate of the health of the nation. NHANES III covers the years 1988 to 1994. Detailed methods used in NHANES III are available for public access at http://www.cdc.gov/nchs/nhanes.htm, and have been published elsewhere [18] .
We limited the present analysis to data released in October 2006 from NHANES III on subjects who had serum measurements of both IGF-I and IGFBP-3 (n = 6061) and to non-pregnant women aged 20 < 50 years (to avoid hormonal differences due to menopause), who attended a morning medical examination and who had fasted for 8 h. We excluded results for those judged by their interviewer to have provided unreliable data, those with missing data for the metabolic syndrome components and subjects who had self-reported diabetes, myocardial infarction and/or stroke (to study an otherwise representative healthy population). This resulted in a final analytic sample of 3281 subjects (1463 men and 1818 women). The insulin sensitivity index was determined using the updated computer HOMA2 (homoeostatic model assessment 2) model (http://www.dtu.ox.ac.uk/homa/index). Insulin resistance was defined as the upper quartile of the HOMA2 distribution.
Measurement of IGF-I and IGFBP-3
IGF-I and IGFBP-3 were measured using standard laboratory protocols by Diagnostic Systems Laboratories. Details of the quality control measures are described elsewhere [19] .
Definition of the metabolic syndrome
We used the updated ATP-III (Adult Treatment Panel III) definition of the metabolic syndrome [20] . This was met when three or more of the following criteria were present: waist circumference 102 cm (40 in) in men and 88 cm (35 in) in women; HDL (high-density lipoprotein)-cholesterol < 1.03 mmol/l (40 mg/dl) in men and < 1.30 mmol/l (50 mg/dl) in women or specific treatment for this lipid abnormality; triacylglycerols (triglycerides) 1.7 mmol/l (150 mg/dl) in men and women or specific treatment for this lipid abnormality; SBP [systolic BP (blood pressure)] 130 mmHg or DBP (diastolic BP) 85 mmHg in men and women or treatment of previously diagnosed hypertension; and fasting glucose 5.6 mmol/l (100 mg/dl) in men and women.
Statistical analysis
Analysis of the NHANES III data was conducted following the recommendations in Analytic and Reporting Guidelines: The Third National Health and Nutrition Examination Survey, NHANES III (1988 to 1994) (http://www.cdc.gov/nchs/data/nhanes/nhanes3/ nh3gui.pdf). We defined a 'low' IGF-I/IGFBP-3 ratio as the lowest gender-specific quartile of the IGF-I/ IGFBP-3 ratio ( 0.06 in men and 0.05 in women), and we then compared the upper three quartiles to define the 'normal' IGF-I/IGFBP-3 ratio. We applied logistic and multiple linear regression models adjusted for age and gender to determine the association between the IGF-I/IGFBP-3 ratio and the metabolic syndrome. Age, race and gender were always included as covariates. The predictive value of each component was assessed by comparing the R 2 values of the models obtained from each group. Incremental additive value was judged by the increase in R 2 obtained when IGF-I, IGBP-3 and the IGF-I/IGFBP-3 ratio were added to the metabolic syndrome components.
To analyse the additional contribution of IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 ratio to detect insulin resistance, we constructed ROC (receiver operating characteristic) curves. To assess whether the areas under the ROC curves obtained using different predictors were significantly different, the method described by Delong et al. [21] was used. All analyses were performed using the SAS Windows version and SUDAAN. 9.0.3 
RESULTS
Descriptive characteristics
Overall, subjects with a low IGF-I/IGFBP-3 ratio were older and had, on average, higher mean values of BMI (body mass index), waist circumference, triacylglycerols, fasting glucose, BP levels and HOMA2 index than subjects with a normal IGF-I/IGFBP-3 ratio (Table 1 ). In addition, the percentage of subjects who met the criteria for insulin resistance and the ATP-III-defined metabolic syndrome was significantly higher in subjects with a low IGF-I/IGFBP-3 ratio. In contrast, subjects with a low IGF-I/IGFBP-3 ratio had significantly lower HDL-cholesterol than with a normal IGF-I/ IGFBP-3 ratio (Table 1) .
Relationships between IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 ratio and the metabolic syndrome
Mean values of the IGF-I/IGFBP-3 ratio decreased significantly as the number of metabolic syndrome components increased (P < 0.0001, as determined by ANOVA; Figure 1 ). Despite the high correlation between IGF-I and IGFBP-3, there were significant differences in their respective correlations with the metabolic syndrome components. We found significant correlations between the IGF-I/IGFBP-3 ratio and all of the metabolic syndrome components, including HOMA2, after adjusting for age, gender and race.
Figure 1 IGF-I/IGFBP-3 ratio distribution according to the number of the metabolic syndrome components
After adjusting for age and race, men in the lowest quartile of the IGF-I/IGFBP-3 ratio were 3.1-fold more likely to meet the ATP-III definition of the metabolic syndrome and twice as likely to be insulin-resistant. Women in the lowest quartile of the IGF-I/IGFBP-3 ratio were 3.6-fold more likely to meet the ATP-III definition of the metabolic syndrome and twice as likely to be insulin-resistant. In both sexes, the lowest quartile of the IGF-I/IGFBP-3 ratio provided significant ORs (odds ratios) for the components of the metabolic syndrome (Table 2) . To evaluate the quantitative levels of the component measures of the metabolic syndrome further, we conducted multiple regression analyses in which the independent variable was the quantitative level of the IGF-I/IGFBP-3 ratio. After controlling for age, gender, race and HOMA2, the IGF-I/IGFBP-3 ratio was still an independent predictor of all of the metabolic syndrome components, except for DBP (Table 3) .
Diagnostic accuracy to detect cardiometabolic risk
To evaluate the diagnostic accuracy of IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 ratio to detect subjects that were insulin-resistant, we constructed ROC curves ( Figure 2) . Overall, the diagnostic accuracy when adding the IGF-I/IGFBP-3 ratio, as judged by the area under the ROC, was improved to 0.760 compared with 0.661 for IGF-I and 0.688 for IGFBP-3 alone (P = 0.01).
DISCUSSION
The novel findings of this cross-sectional analysis of a representative multi-ethnic sample of the U.S. civilian general population are that a low IGF-I/IGFBP-3 ratio was significantly associated with high cardiometabolic risk, specifically the metabolic syndrome and/or insulin resistance. In addition, the IGF-I/IGFBP-3 ratio had a stronger association with all of the metabolic syndrome components than either IGF-I or IGFBP-3 alone. A low IGF-I/IGFBP-3 ratio was associated with an approx. 3-fold increased likelihood of having the metabolic syndrome in both men and women. Given the different and opposing mechanistic effects of IGF-I and IGFBP-3, these findings suggest for the first time that the IGF-I/ IGFBP-3 ratio may provide a potential pathway that leads to the development of the risk-factor-clustering phenomenon. This pathway merits further exploration.
Mechanistic considerations
IGFBP-3 binds to IGF-I in plasma, prolonging the halflife in the circulation and blocking its interactions with the IGF-I receptor [22] . At the tissue level, the affinity of IGFBP-3 for IGF-I reduces the binding of cells to IGFBP-3, hence permitting free binding between IGF-I and its receptors [11, 13] . IGF-I homoeostasis is complicated, and the binding proteins form complexes with IGF-I to modulate its actions. IGFBP-3, which is regulated by GH (growth hormone) and IGF-I, serves as the main reservoir for plasma IGF-I. Conversely, IGFBP-1 is mainly regulated by insulin and is thought to be an acute regulator of IGF-I. Depending on the metabolic condition, IGFBPs either inhibit or potentiate the actions of IGF-I. IGFBP-1 is a dynamic regulator of free IGF-I, especially coming from the liver and has diurnal variation; conversely, IGFBP-3 is a slower, more stable, regulator of free systemic IGF-I that does not show diurnal variation [16] .
Experimental myocardial infarction models suggest that IGF-I may promote survival of myocytes exposed to ischaemic injury in part by enhancing glucose uptake [23, 24] . In addition, TNF-α (tumour necrosis factor-α) reduces IGF-I and increases IGFBP-3 in vascular smooth muscle cells, which may, in turn, decrease cell survival in atherosclerotic plaques, promoting plaque rupture and leading to the development of the atherosclerotic process [25] .
With regard to IGFBP-3 and its role in the pathogenesis of cardiometabolic disease, previous studies have shown divergent results. Both high and low serum IGFBP-3 concentrations have been related to cardiovascular disease [16, 26, 27] . In our present study, high serum IGFBP-3 concentrations were associated with the metabolic syndrome and insulin resistance; however, this issue remains controversial, as there are factors known to affect IGFBP-3 concentrations, such age, cardiometabolic status, time the blood sample is taken and/or dietary factors [28] . Future studies should aim to standardize the conditions under which measurements are made in order to have valid comparisons between different studies.
Strengths and limitations
An important limitation of our present study is the cross-sectional design that does not allow us to determine causality. Another important limitation is that we did not analyse IGFBP-1 because it was not available from NHANES III. A strength of our present study is the use of a U.S. national representative sample with a large sample size. NHANES was designed with the aim that the results of this analysis are generalizable to all persons in the U.S. NHANES uses a stratified multi-stage probability sampling design to produce estimates generalizable to the U.S. population.
Practical implications
The present study adds to a growing body of evidence linking the IGF system to cardiovascular risk in both men and women [29] . Understanding the complex pathways that lead to the metabolic syndrome cluster phenomenon and cardiovascular disease is paramount. A low IGF-I/IGFBP-3 ratio suggests that increased IGFBP-3 reduces the availability of IGF-I, thus detecting subjects at a particularly high cardiometabolic risk that would otherwise be missed. The ability of a low IGF-I/ IGFBP-3 ratio to detect subjects at high cardiovascular risk demands prospective investigation. Its use should be evaluated to determine intervention effects or disease progression in clinical studies. Clinical use would have to await confirmation in longitudinal studies of cardiovascular disease end points and wide availability of inexpensive well-standardized assays. In addition, there might be some future therapeutical implications, due to the recent introduction of a new complex in which IGF-I is bound to IGFBP-3, which has been found to be safe and efficacious in humans and it is being developed as part of new diabetic therapeutics [8, 30] .
Conclusions
In conclusion, we have found that the IGF-I/IGFBP-3 ratio is significantly associated with the metabolic syndrome. A low IGF-I/IGFBP-3 ratio may provide a mechanistic insight into the metabolic pathways among the different cardiometabolic entities.
